The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the CenturyInvestorPlace • 07/01/21
CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological DiseasesZacks Investment Research • 06/16/21
CRISPR Therapeutics, Capsida Collaborate To Develop Gene-Edited Therapies For Neurological DiseasesBenzinga • 06/15/21
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich's AtaxiaGlobeNewsWire • 06/15/21
Monday's Analyst Upgrades and Downgrades: Chipotle, CRISPR, Hess Midstream, iMedia, Kinder Morgan, Wendy's and More24/7 Wall Street • 06/14/21
Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy TrialsBenzinga • 06/11/21
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual MeetingBusiness Wire • 06/11/21
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 42nd Annual Global Healthcare Broker Conference Call - (Transcript)Seeking Alpha • 06/08/21
CRISPR Therapeutics AG (CRSP) CEO Samarth Kulkarni on William Blair & Company 41st Annual Growth Stock Conference (Transcript)Seeking Alpha • 06/03/21
CRISPR Therapeutics AG (CRSP) CEO Sam Kulkarni Presents at Jefferies Virtual Healthcare Conference (Transcript)Seeking Alpha • 06/01/21
CRISPR Therapeutics AG (CRSP) Down 12.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 05/27/21